{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T22:23:17Z","timestamp":1770243797530,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Frankfurt"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Outcomes of adjuvant (aRT) or salvage radiation therapy (sRT) after radical prostatectomy are under investigation regarding cancer-control outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Relying on the University Cancer Center database elaborating differences in metastasis-free (MFS), cancer-specific (CSS) and overall survival (OS) of aRT vs. sRT-treated patients between 2014\u20132024. Sensitivity analyses addressed high-risk patients with pN1 and\/or Gleason score\u00a08\u201310 and\/or pT3\u20134 stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 1862 patients, 7.1% underwent aRT and 93% were in the sRT group. Median PSA at sRT was 0.33\u202fng\/ml. Patients with aRT harbored significantly worse baseline tumor and pathological characteristics such as PSA level (12.0 vs. 7.6\u202fng\/ml), Gleason score\u00a09\u201310 (30% vs.\u00a09.8%), D\u2019Amico high risk prostate cancer (97% vs.\u00a056%), as well as pT3\u20134, pN1 and positive surgical margins rates (all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u20090.001). Similar observations were made for high-risk patients. No differences were observed for aRT vs. sRT with 60-month MFS rates of 85.1% vs. 95.4% (hazard ratio [HR] 0.60,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.18). 60-months CSS-rates of 96.8% vs. 99.1% and 60-month OS-rates of 91.0% vs. 89.1% respectively (all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f\u2265\u20090.15). Neither sensitivity analyses of high-risk patients nor multivariable adjusted Cox regression models revealed significant differences regarding MFS, CSS or OS in aRT vs. SRT comparison (all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f\u2265\u20090.05), despite aRT showing qualitatively better OS results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Within real-world setting, patients undergoing aRT harbor wore tumor characteristics. However, these differences did not translate into significant differences of mid-term oncological outcomes, relative to sRT patients. Similar observations were made within analyses of high-risk patients with pT3\u20134 and\/or Gleason\u00a08\u201310 and\/or pN1 stage, nevertheless aRT showed slightly higher OS rates within this subgroup.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-025-02400-4","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T12:05:27Z","timestamp":1746533127000},"page":"129-138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real world comparison of adjuvant vs. salvage radiation therapy on cancer-control outcomes after radical prostatectomy"],"prefix":"10.1007","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4338-0889","authenticated-orcid":false,"given":"Mike","family":"Wenzel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Burdenski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Tselis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Brandts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marit","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Koellermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Humke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Siech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Hoeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Severine","family":"Banek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix K. H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"2400_CR1","unstructured":"Cornford P, Tilki D, van den Bergh RCN et al EAU guidelines on prostate cancer. Edn. presented at the EAU annual congress paris 2024"},{"issue":"3","key":"2400_CR2","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","volume":"181","author":"IM Thompson","year":"2009","unstructured":"Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a\u00a0randomized clinical trial. J\u00a0Urol 181(3):956\u2013962. https:\/\/doi.org\/10.1016\/j.juro.2008.11.032","journal-title":"J Urol"},{"issue":"9858","key":"2400_CR3","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","volume":"380","author":"M Bolla","year":"2012","unstructured":"Bolla M, van Poppel H, Tombal B et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a\u00a0randomised controlled trial (EORTC trial 22911). Lancet 380(9858):2018\u20132027. https:\/\/doi.org\/10.1016\/S0140-6736(12)61253-7","journal-title":"Lancet"},{"issue":"5","key":"2400_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.eururo.2019.07.001","volume":"76","author":"G Hackman","year":"2019","unstructured":"Hackman G, Taari K, Tammela TL et al (2019) Randomised trial of Adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension. Eur Urol 76(5):586\u2013595. https:\/\/doi.org\/10.1016\/j.eururo.2019.07.001","journal-title":"Eur Urol"},{"issue":"2","key":"2400_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","volume":"66","author":"T Wiegel","year":"2014","unstructured":"Wiegel T, Bartkowiak D, Bottke D et al (2014) Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02\/AUO AP 09\/95\u00a0trial. Eur Urol 66(2):243\u2013250. https:\/\/doi.org\/10.1016\/j.eururo.2014.03.011","journal-title":"Eur Urol"},{"issue":"7","key":"2400_CR6","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.annonc.2024.03.010","volume":"35","author":"CC Parker","year":"2024","unstructured":"Parker CC, Petersen PM, Cook AD et al (2024) Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Ann Oncol 35(7):656\u2013666. https:\/\/doi.org\/10.1016\/j.annonc.2024.03.010","journal-title":"Ann Oncol"},{"issue":"7","key":"2400_CR7","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.3390\/cancers14071688","volume":"14","author":"M Terlizzi","year":"2022","unstructured":"Terlizzi M, Limkin EJ, Moukasse Y, Blanchard P (2022) Adjuvant or salvage radiation therapy for prostate cancer after prostatectomy: current status, controversies and perspectives. Cancers 14(7):1688. https:\/\/doi.org\/10.3390\/cancers14071688","journal-title":"Cancers"},{"issue":"10","key":"2400_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","volume":"21","author":"A Kneebone","year":"2020","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM et al (2020) Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a\u00a0randomised, controlled, phase\u00a03, non-inferiority trial. Lancet Oncol 21(10):1331\u20131340. https:\/\/doi.org\/10.1016\/S1470-2045(20)30456-3","journal-title":"Lancet Oncol"},{"issue":"10","key":"2400_CR9","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos P, Chabaud S, Latorzeff I et al (2020) Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a\u00a0randomised, phase\u00a03\u00a0trial. lancet Oncol 21(10):1341\u20131352. https:\/\/doi.org\/10.1016\/S1470-2045(20)30454-X","journal-title":"lancet Oncol"},{"issue":"10260","key":"2400_CR10","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","volume":"396","author":"CL Vale","year":"2020","unstructured":"Vale CL, Fisher D, Kneebone A et al (2020) Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a\u00a0prospectively planned systematic review and meta-analysis of aggregate data. Lancet Lond Engl 396(10260):1422\u20131431. https:\/\/doi.org\/10.1016\/S0140-6736(20)31952-8","journal-title":"Lancet Lond Engl"},{"issue":"20","key":"2400_CR11","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1200\/JCO.20.03714","volume":"39","author":"D Tilki","year":"2021","unstructured":"Tilki D, Chen MH, Wu J et al (2021) Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death. J\u00a0Clin Oncol Off J Am Soc Clin Oncol 39(20):2284\u20132293. https:\/\/doi.org\/10.1200\/JCO.20.03714","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"20","key":"2400_CR12","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1200\/JCO.21.02800","volume":"40","author":"D Tilki","year":"2022","unstructured":"Tilki D, Chen MH, Wu J, Huland H, Graefen M, D\u2019Amico AV (2022) Adjuvant versus early salvage radiation therapy after radical prostatectomy for pN1 prostate cancer and the risk of death. J\u00a0Clin Oncol Off J Am Soc Clin Oncol 40(20):2186\u20132192. https:\/\/doi.org\/10.1200\/JCO.21.02800","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"2400_CR13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/bju.13679","volume":"119","author":"D Tilki","year":"2017","unstructured":"Tilki D, Preisser F, Tennstedt P et al (2017) Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy. bju Int 119(5):717\u2013723. https:\/\/doi.org\/10.1111\/bju.13679","journal-title":"bju Int"},{"issue":"13","key":"2400_CR14","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.22.02489","volume":"41","author":"D Tilki","year":"2023","unstructured":"Tilki D, Chen MH, Wu J et al (2023) Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death. J\u00a0Clin Oncol Off J Am Soc Clin Oncol 41(13):2428\u20132435. https:\/\/doi.org\/10.1200\/JCO.22.02489","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"2400_CR15","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.euf.2021.07.008","volume":"8","author":"M Wenzel","year":"2022","unstructured":"Wenzel M, W\u00fcrnschimmel C, Chierigo F et al (2022) Nomogram predicting downgrading in national comprehensive cancer network high-risk prostate cancer patients treated with radical prostatectomy. Eur Urol Focus 8(5):1133\u20131140. https:\/\/doi.org\/10.1016\/j.euf.2021.07.008","journal-title":"Eur Urol Focus"},{"key":"2400_CR16","doi-asserted-by":"publisher","first-page":"990851","DOI":"10.3389\/fonc.2022.990851","volume":"12","author":"L Nocera","year":"2022","unstructured":"Nocera L, Stolzenbach LF, Ruvolo CC et al (2022) Predicting the probability of pT3 or higher pathological stage at radical prostatectomy: COVID\u00a019-specific considerations. Front Oncol 12:990851. https:\/\/doi.org\/10.3389\/fonc.2022.990851","journal-title":"Front Oncol"},{"issue":"9","key":"2400_CR17","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3390\/diagnostics13091614","volume":"13","author":"CC Garcia","year":"2023","unstructured":"Garcia CC, Wenzel M, Piccinelli ML et al (2023) External tertiary-care-hospital validation of the epidemiological SEER-based nomogram predicting downgrading in high-risk prostate cancer patients treated with radical prostatectomy. Diagn Basel Switz 13(9):1614. https:\/\/doi.org\/10.3390\/diagnostics13091614","journal-title":"Diagn Basel Switz"},{"issue":"5","key":"2400_CR18","doi-asserted-by":"publisher","first-page":"e175230","DOI":"10.1001\/jamaoncol.2017.5230","volume":"4","author":"WL Hwang","year":"2018","unstructured":"Hwang WL, Tendulkar RD, Niemierko A et al (2018) Comparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological features. JAMA Oncol 4(5):e175230. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5230","journal-title":"JAMA Oncol"},{"issue":"3","key":"2400_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000536609","volume":"108","author":"S Sigg","year":"2024","unstructured":"Sigg S, Arnold W, Grossmann NC et al (2024) Why do men reject adjuvant radiotherapy following radical prostatectomy? a\u00a0systematic survey. urol Int 108(3):211\u2013218. https:\/\/doi.org\/10.1159\/000536609","journal-title":"urol Int"},{"issue":"6","key":"2400_CR20","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.eururo.2016.07.028","volume":"71","author":"N Fossati","year":"2017","unstructured":"Fossati N, Karnes RJ, Boorjian SA et al (2017) Long-term impact of adjuvant versus early salvage radiation therapy in pT3N0 prostate cancer patients treated with radical prostatectomy: results from a\u00a0multi-institutional series. Eur Urol 71(6):886\u2013893. https:\/\/doi.org\/10.1016\/j.eururo.2016.07.028","journal-title":"Eur Urol"},{"issue":"3","key":"2400_CR21","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.radonc.2010.07.008","volume":"97","author":"T Budiharto","year":"2010","unstructured":"Budiharto T, Perneel C, Haustermans K et al (2010) A\u00a0multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. Radiother Oncol 97(3):474\u2013479. https:\/\/doi.org\/10.1016\/j.radonc.2010.07.008","journal-title":"Radiother Oncol"},{"issue":"1","key":"2400_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/COC.0b013e318287bb6b","volume":"38","author":"MV Mishra","year":"2015","unstructured":"Mishra MV, Scher ED, Andrel J et al (2015) Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: comparative analysis of long-term outcomes. Am J Clin Oncol 38(1):55\u201360. https:\/\/doi.org\/10.1097\/COC.0b013e318287bb6b","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"2400_CR23","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1016\/j.prro.2016.10.010","volume":"7","author":"DL Buscariollo","year":"2017","unstructured":"Buscariollo DL, Drumm M, Niemierko A et al (2017) Long-term results of adjuvant versus early salvage postprostatectomy radiation: a\u00a0large single-institutional experience. Pract Radiat Oncol 7(2):e125\u2013e133. https:\/\/doi.org\/10.1016\/j.prro.2016.10.010","journal-title":"Pract Radiat Oncol"},{"issue":"11","key":"2400_CR24","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/j.1464-410X.2010.09447.x","volume":"106","author":"AV D\u2019Amico","year":"2010","unstructured":"D\u2019Amico AV, Chen MH, Sun L et al (2010) Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. bju Int 106(11):1618\u20131622. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09447.x","journal-title":"bju Int"},{"issue":"1","key":"2400_CR25","doi-asserted-by":"publisher","first-page":"7.e1","DOI":"10.1016\/j.urolonc.2021.06.008","volume":"40","author":"M Wenzel","year":"2022","unstructured":"Wenzel M, Hussein R, Maurer T et al (2022) PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy. Urol Oncol 40(1):7.e1\u20137.e8. https:\/\/doi.org\/10.1016\/j.urolonc.2021.06.008","journal-title":"Urol Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02400-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-025-02400-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02400-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T09:06:30Z","timestamp":1770195990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-025-02400-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2400"],"URL":"https:\/\/doi.org\/10.1007\/s00066-025-02400-4","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.\u00a0Wenzel, K.\u00a0Burdenski, N.\u00a0Tselis, C.\u00a0R\u00f6del, C.\u00a0Brandts, M.\u00a0Ahrens, J.\u00a0Koellermann, M.\u00a0Graefen, C.\u00a0Humke, C.\u00a0Siech, B.\u00a0Hoeh, S.\u00a0Banek, F.K.\u00a0H.\u00a0Chun and P.\u00a0Mandel declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}